CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 4933-4938

  Paz, Maria F ^a   Yaya Tur, Ricard ^b   Rojas Marcos, Iñigo ^c   Reynes, Gaspar ^d   Pollan, Marina ^e   Aguirre Cruz, Lucinda ^c,f   García Lopez, Jose Luis ^g   Piquer, Jose ^h   Safont, María Jose ^h   Balaña, Carmen ⁱ   Sanchez Cespedes, Montserrat ^a   García Villanueva, Mercedes ^a   Arribas, Leoncio ^b   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e CARLOS III INSTITUTE OF HEALTH   (Spain)

^f NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL DE LA RIBERA   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DRUG RESPONSE; ENZYME MECHANISM; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; ALKYLATING AGENTS; BRAIN NEOPLASMS; CARMUSTINE; CPG ISLANDS; DACARBAZINE; DNA; DNA METHYLATION; DNA REPAIR; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME;

EID: 4143084896     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0392     Document Type: Article

References (48)

1. th ed. Philadelphia: Lippincott-Raven; 1997. p. 405-18.
2. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990; 1990;233:117-26.
3. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
4. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004;23:1-8.
5. Belanich M, Pastorm M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-8.
6. 6-Methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998;58: 1068-73.
7. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5.
8. 6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-14.
9. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
10. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003;4: 37-44.
11. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1997;57:3672-7.
12. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997;17:5612-9.
13. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
14. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
15. Herfarth KK, Brent TP, Danam RP, et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 1999; 24:90-8.
16. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
17. 6-Methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9: 1461-8.
18. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
19. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66.
20. van den Bent MJ, Taphoorn MJ, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8.
21. Chang SM, Theodosopoulos P, Lamborn K, et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004;100:605-11.
22. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001;7:2309-17.
23. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11.
24. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 2001;7:421-8.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
26. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (Bethesda) 2002;94:26-32.
27. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-9.
28. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912-20.
29. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
30. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol; 2003;4:351-8.
31. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
32. Weinstein JN. Pharmacogenomics: teaching old drugs new tricks. N Engl J Med 2000;343:1408-9.
33. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl) 1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003; 304:661-8.
34. 6-benzyl-2′-deoxyguanosine. Clin Cancer Res 2003;9:3801-7.
35. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
36. 6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003;25:241-8.
37. 6- methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea- based chemotherapy. Neurosurgery 2004;54:349-57.
38. Adonizio CS, Babb JS, Maiale C, et al. Temozolomide in non-small cell lung cancer: preliminary results of a Phase II trial in previously treated patients. Clin Lung Cancer 2002;3:254-8.
39. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002;29:518-24.
40. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;21:3351-6.
41. 6-Methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J Cancer 1998;77:919-22.
42. 6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res 1999;59:3059-63.
43. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 1987;3:837-47.
44. 6-alkylguanine-DNA alkyltransferases. Cancer Res 2000;60:5464-9.
45. 6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 2002;93:184-9.
46. 6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002;9:371-9.
47. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003;9:223-7.
48. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176-84.